In the long human struggle against the scarcity of life-giving organs, a 66-year-old man named Tim Andrews quietly rewrote what is possible: for 271 days, a genetically engineered pig kidney kept him alive and free from dialysis, until a human organ arrived to take its place. His case, documented at Massachusetts General Hospital and published in The Lancet, is the first recorded instance of a xenograft serving as a true bridge to human transplantation — not a final answer, but a passage. It does not resolve the organ shortage, but it proves that the gap between waiting and receiving might, at
Pig kidney xenotransplant bridges gap to human donor organ in landmark case
No direct casualties or displacement; patient experienced successful transplant transition with improved quality of life avoiding dialysis for 271 days.
A pig kidney bought him time—nine months without dialysis.
Mark
So Andrews got a pig kidney, and then nine months later got a human kidney. That's the headline. But what does it actually mean for the thousands of people on dialysis right now?
Mimi
It means the pig kidney bought him time. He didn't need dialysis for 271 days. That's nine months of his life back—no needles, no machines, no four-hour sessions three times a week. For most kidney patients, that's unimaginable.
Luke
But he still needed the human kidney eventually. The pig kidney failed. So it's not a cure, it's a pause.
Mimi
Exactly. It's a pause. And right now, there is no pause. You're on dialysis until a human organ comes, or you die waiting. A pause is revolutionary.
Mark
The kidney failed because of microvascular injury after they reduced his immunosuppression. That sounds like a fixable problem.
Mimi
It might be. The paper says the injury has implications for how doctors design immunosuppressive strategies and how they genetically engineer the donor pigs. It's not a dead end; it's a clue.
Luke
But we don't know yet if those fixes will work. We have one patient. One.
Mark
True. But the first human-to-human kidney transplant was also one patient, in 1954. How many people are waiting for kidneys right now?
Mimi
Tens of thousands in the United States alone. The shortage is the crisis in transplantation.
Luke
And we still don't know if xenotransplants will ever be durable enough to be a real solution. This case shows promise, but it's early.
Mark
What about infection? That was always the fear with animal organs.
Mimi
No pig pathogens were detected in Andrews. That's significant. It suggests the genetic engineering is working to prevent cross-species transmission.
Luke
In one patient, over nine months. We need more data.
Mark
Fair. But isn't that what these early studies are for?
Mimi
Yes. And Andrews volunteered for it. He knew the risks. That matters.
Il Polso
- Tens of thousands of kidney patients remain tethered to dialysis machines while waiting for organs that may never come — the shortage is not a future crisis, it is the present one.
- Tim Andrews' pig kidney functioned immediately after transplant, survived an early immune rejection episode, and kept him dialysis-free for nine months — shattering every previous xenograft survival record in a living human.
- An infection forced doctors to reduce his immunosuppression, and the pig kidney began to fail from within — microvascular injury spreading through the organ's tiny blood vessels — revealing a critical vulnerability in current protocols.
- A human donor kidney arrived in time, was transplanted successfully, and showed no sign that the pig organ had primed Andrews' immune system against it — the bridge had held.
- Researchers now face the next set of questions: how to refine genetic engineering in donor pigs, how to manage immunosuppression without sacrificing the graft, and whether xenotransplantation can evolve from a temporary bridge into a permanent destination therapy.
In the long human struggle against the scarcity of life-giving organs, a 66-year-old man named Tim Andrews quietly rewrote what is possible: for 271 days, a genetically engineered pig kidney kept him alive and free from dialysis, until a human organ arrived to take its place. His case, documented at Massachusetts General Hospital and published in The Lancet, is the first recorded instance of a xenograft serving as a true bridge to human transplantation — not a final answer, but a passage. It does not resolve the organ shortage, but it proves that the gap between waiting and receiving might, at last, be crossable.
Tim Andrews was 66 when surgeons at Massachusetts General Hospital placed a genetically engineered pig kidney into his body in January 2025. For the next nine months, it worked — filtering his blood, sparing him from dialysis, keeping him alive. In January 2026, a human kidney from a deceased donor became available, and the pig kidney's role was finished. That sequence had never been documented before.
The case, published in The Lancet by researchers at Mass General Brigham, matters because of what it proves: a genetically modified animal organ can sustain a human life long enough for a human organ to arrive. Andrews survived 271 dialysis-free days — the longest xenograft survival ever recorded in a living human — and then transitioned successfully to a human transplant, with no sign that his immune system had been sensitized against it.
The backdrop is a crisis with no easy exit. End-stage kidney disease leaves patients dependent on dialysis for hours at a time, several days a week. Transplantation is the only real cure, but demand vastly outpaces supply. Xenotransplantation has long been imagined as a solution, but the science has been fragile. The first pig kidney transplant into a living human, also at Mass General, occurred in 2024; that patient survived 52 days before dying of unrelated cardiac causes. No previous xenograft had lasted beyond two months.
Andrews' kidney was different. The donor pig had been genetically edited to reduce rejection and cross-species infection risk. The organ functioned immediately. An early T-cell rejection episode was treated and resolved. No pig pathogens appeared in his blood. Then, around the six-month mark, an infection required doctors to reduce his immunosuppression — and the pig kidney began to deteriorate. Microvascular injury spread through the organ. Inflammation followed. But a human kidney arrived before the situation became fatal, and it worked immediately.
The failure of the xenograft points to real gaps: in immunosuppressive management, in the genetic engineering of donor animals, in monitoring protocols. But lead author Leonardo Riella sees a clear trajectory — xenotransplantation as a bridge first, and potentially as a permanent therapy if durability can be improved. Senior author Tatsuo Kawai notes that Massachusetts General performed the world's first live donor kidney transplant in 1954. Seven decades later, the hospital is still redefining where a kidney can come from — and what it means to wait for one.
Tim Andrews was 66 years old when surgeons at Massachusetts General Hospital placed a genetically engineered pig kidney into his body in January 2025. For the next nine months, something remarkable happened: the organ worked. It filtered his blood. It kept him alive without dialysis. Then, in January 2026, Andrews received a human kidney from a deceased donor, and the pig kidney's job was done.
This sequence—pig kidney, then human kidney—had never been documented before. Andrews' case, published this week in The Lancet by researchers at Mass General Brigham, represents both a proof of concept and a window into how xenotransplantation might reshape the landscape of organ transplantation. He survived 271 days with the porcine graft, the longest dialysis-free period ever recorded following a pig kidney transplant in a living human. More importantly, he lived long enough to receive a human organ, demonstrating that a genetically modified animal kidney could serve as a genuine bridge—not a dead end, but a way station.
The context for this matters. Kidney disease kills. End-stage renal failure leaves patients dependent on dialysis, a grueling routine of blood filtration that demands hours of their time several times a week. The only real cure is transplantation. But there are far more people who need kidneys than there are kidneys available. The shortage is the defining crisis in transplantation right now, and it has no easy solution. Xenotransplantation—using animal organs in human recipients—has long been imagined as a potential answer, but the science has been fragile. The world's first pig kidney transplant into a living human, also at Massachusetts General, occurred in 2024. That patient survived 52 days before dying of cardiac causes unrelated to the transplant. No previous xenograft had lasted beyond two months.
Andrews' kidney was different. The pig had been genetically edited to prevent rejection and reduce the risk of cross-species infection. When the organ was placed, it functioned immediately. Early on, Andrews' immune system mounted an attack—a T-cell-mediated rejection episode—but doctors treated it and the rejection resolved. No pig pathogens were detected in his blood. For nine months, he lived without dialysis, a freedom that most kidney patients never experience while waiting for a human organ.
Then, around the six-month mark, Andrews developed an infection. His doctors reduced his immunosuppressive medications to help his body fight it. The reduction had consequences. The pig kidney began to deteriorate. Microvascular injury—tiny damage to the blood vessels within the organ—developed and spread. Inflammation followed. The xenograft was failing. But by then, a human kidney had become available. Andrews received it in January 2026, and it worked immediately, with no signs that his time with the pig kidney had sensitized his immune system against human organs.
The findings raise as many questions as they answer. The microvascular injury that destroyed the pig kidney points to gaps in how doctors manage immunosuppression in xenotransplant recipients. It suggests that the genetic engineering of donor pigs may need refinement. It indicates that monitoring protocols require rethinking. But it also proves something fundamental: a pig kidney can sustain a human life long enough for a human kidney to arrive. For patients trapped in the waiting game, that is not a small thing.
Leonardo Riella, the lead author, frames the vision plainly: xenotransplantation could initially serve as a bridge, allowing patients to escape dialysis while they wait. Eventually, if durability improves, it might become a destination therapy in its own right—a permanent solution rather than a temporary one. Tatsuo Kawai, the senior author and director of the transplantation tolerance center, connects this work to Massachusetts General's history: the hospital performed the world's first live donor kidney transplant in 1954. Seven decades later, it is still pushing the boundaries of what a kidney can be and where it can come from.
Riella added a note about the human dimension. The patients who volunteer for these early-stage studies are pioneers, he said. They step forward knowing the risks, trusting the science, willing to advance knowledge that will benefit others. Without that courage, none of this would be possible. Andrews' 271 days with a pig kidney were not just a medical milestone. They were a gift to everyone waiting for an organ that may never come.
Citazioni salienti
Xenotransplantation could help address the organ shortage—initially as a bridge to get patients off dialysis while they wait for a human donor kidney, and potentially, as we establish long-term safety and durability, as a destination therapy in its own right.— Leonardo Riella, MD, PhD, lead author and nephrologist at Mass General Brigham
The patients are the true pioneers here. By stepping forward and being willing to participate in these early-stage studies, they are advancing the science.— Leonardo Riella
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Health & Medicine